STOCK TITAN
  1. Home
  2. Sec-filings
  3. DYN
  4. [Form 4] Dyne Therapeutics, Inc. Insider Trading Activity

Dyne Therapeutics (DYN) director awarded 35,152 stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Dyne Therapeutics, Inc. director Carlo Incerti received a grant of stock options on June 5, 2026. The award covers 35,152 options to purchase Common Stock at an exercise price of $17.04 per share, held directly.

The options expire on June 4, 2036 and are scheduled to vest in full on the earlier of June 5, 2027 or the date of Dyne Therapeutics’ 2027 Annual Meeting of Stockholders, provided Incerti continues in service. Following this grant, he holds 35,152 derivative securities linked to common shares.

Positive

  • None.

Negative

  • None.
Insider Incerti Carlo
Role null
Type Security Shares Price Value
Grant/Award Stock option (right to buy) 35,152 $0.00 --
Holdings After Transaction: Stock option (right to buy) — 35,152 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Options granted 35,152 options Stock option grant on June 5, 2026
Exercise price $17.04 per share Conversion or exercise price for options
Underlying shares 35,152 shares Common Stock underlying the options
Expiration date June 4, 2036 Option expiration for this grant
Vesting date trigger Earlier of June 5, 2027 or 2027 annual meeting Full vesting schedule subject to continued service
Holdings after grant 35,152 derivative securities Total options following this transaction
Stock option (right to buy) financial
"security_title: "Stock option (right to buy)""
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
Common Stock financial
"underlying_security_title: "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Annual Meeting of Stockholders financial
"the date of the Issuer's 2027 Annual Meeting of Stockholders"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Incerti Carlo
(Last)(First)(Middle)
C/O DYNE THERAPEUTICS, INC.
1560 TRAPELO ROAD
(Street)
WALTHAM MASSACHUSETTS 02451
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Dyne Therapeutics, Inc. [ DYN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock option (right to buy)$17.0406/05/2026A35,152 (1)06/04/2036Common Stock35,152$0.0035,152D
Explanation of Responses:
1. This option was granted on June 5, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 5, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.
/s/ Ron Caponigro, Attorney-in-Fact06/09/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Dyne Therapeutics (DYN) director Carlo Incerti report?

Carlo Incerti reported receiving a stock option grant, not an open-market trade. He was awarded options covering 35,152 shares of Dyne Therapeutics Common Stock as compensation, recorded as a derivative acquisition under code A on the Form 4 insider report.

How many Dyne Therapeutics (DYN) shares are covered by Carlo Incerti’s new options?

The option grant covers 35,152 underlying shares of Dyne Therapeutics Common Stock. These are derivative securities giving the right to buy shares in the future, rather than shares purchased directly in the market at the time of the Form 4 filing.

What is the exercise price and expiration date of Carlo Incerti’s Dyne Therapeutics options?

The options have an exercise price of $17.04 per share and expire on June 4, 2036. This means Incerti may choose to buy Dyne Therapeutics shares at $17.04 before that expiration date, subject to the options vesting as scheduled.

When do Carlo Incerti’s Dyne Therapeutics (DYN) stock options vest?

The options are scheduled to vest in full on the earlier of June 5, 2027 or the date of Dyne Therapeutics’ 2027 Annual Meeting of Stockholders. Vesting requires that Incerti continue his service with the company through the applicable vesting date.

Did Carlo Incerti buy or sell Dyne Therapeutics (DYN) shares in the market?

No market purchase or sale is reported. The Form 4 shows a grant of stock options with transaction code A, meaning a grant, award, or other acquisition. It reflects compensation in options, not a discretionary buy or sell in the open market.